Moreover, IBD patients who exclusively received TNF inhibitor dose intensification as a strategy to overcome immunogenic LOR were less likely to achieve the three endpoints compared to those who received immunomodulator combination therapy (Fig. 2). Here, TNF is linked to inflammatory bowel disease.